![John Tsai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Tsai
Technik-/Wissenschafts-/F&E-Leiter bei
DAIICHI SANKYO COMPANY, LIMITED
Profil
Gegenwärtig ist John Tsai Chief Medical Officer bei der Novartis AG. In seiner früheren Laufbahn war Dr. Tsai Chief Medical Officer & SVP-Global Medical bei Amgen, Inc. und Head-Clinical Development bei Bristol Myers Squibb Co. Er promovierte an der University of Louisville School of Medicine und erhielt einen Bachelor-Abschluss von der Washington University in St. Louis.
Aktive Positionen von John Tsai
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNCONA LIMITED | Corporate Officer/Principal | 01.01.2023 |
| DAIICHI SANKYO COMPANY, LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2026 |
Forcefield Therapeutics Ltd.
 Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Vorstandsvorsitzender | 27.09.2023 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Vorsitzender | 16.10.2023 |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Vorsitzender | - |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von John Tsai
| Unternehmen | Position | Ende |
|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Private Equity Investor | 01.02.2026 |
| BLUEPRINT MEDICINES CORPORATION | Direktor/Vorstandsmitglied | 17.07.2025 |
| NOVARTIS AG | Technik-/Wissenschafts-/F&E-Leiter | 15.05.2022 |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von John Tsai
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
65
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Daiichi Sankyo Co., Ltd.
 Daiichi Sankyo Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the manufacture and sale of pharmaceutical products | Health Technology |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Commercial Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
University of Louisville School of Medicine
 University of Louisville School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Health Technology |
Purespring Therapeutics Ltd.
Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Health Technology |
Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Health Technology |
